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BACKGROUND: Progerin, an aberrant protein that accumulates with age, causes 
the rare genetic disease Hutchinson-Gilford progeria syndrome (HGPS). Patients 
who have HGPS exhibit ubiquitous progerin expression, accelerated aging and 
atherosclerosis, and die in their early teens, mainly of myocardial infarction or 
stroke. The mechanisms underlying progerin-induced atherosclerosis remain 
unexplored, in part, because of the lack of appropriate animal models.
METHODS: We generated an atherosclerosis-prone model of HGPS by crossing 
apolipoprotein E–deficient (Apoe–/–) mice with LmnaG609G/G609G mice ubiquitously 
expressing progerin. To induce progerin expression specifically in macrophages or 
vascular smooth muscle cells (VSMCs), we crossed Apoe–/–LmnaLCS/LCS mice with 
LysMCre and SM22αCre mice, respectively. Progerin expression was evaluated by 
polymerase chain reaction and immunofluorescence. Cardiovascular alterations 
were determined by immunofluorescence and histology in male mice fed normal 
chow or a high-fat diet. In vivo low-density lipoprotein retention was assessed 
by intravenous injection of fluorescently labeled human low-density lipoprotein. 
Cardiac electric defects were evaluated by electrocardiography.
RESULTS: Apoe–/–LmnaG609G/G609G mice with ubiquitous progerin expression 
exhibited a premature aging phenotype that included failure to thrive and 
shortened survival. In addition, high-fat diet–fed Apoe–/–LmnaG609G/G609G mice 
developed a severe vascular pathology, including medial VSMC loss and lipid 
retention, adventitial fibrosis, and accelerated atherosclerosis, thus resembling 
most aspects of cardiovascular disease observed in patients with HGPS. The same 
vascular alterations were also observed in Apoe–/–LmnaLCS/LCSSM22αCre mice 
expressing progerin specifically in VSMCs, but not in Apoe–/–LmnaLCS/LCSLysMCre 
mice with macrophage-specific progerin expression. Moreover, Apoe–/–LmnaLCS/
LCSSM22αCre mice had a shortened lifespan despite the lack of any overt aging 
phenotype. Aortas of ubiquitously and VSMC-specific progerin-expressing 
mice exhibited increased retention of fluorescently labeled human low-density 
lipoprotein, and atheromata in both models showed vulnerable plaque features. 
Immunohistopathological examination indicated that Apoe–/–LmnaLCS/LCSSM22αCre 
mice, unlike Apoe–/–LmnaG609G/G609G mice, die of atherosclerosis-related causes.
CONCLUSIONS: We have generated the first mouse model of progerin-induced 
atherosclerosis acceleration, and demonstrate that restricting progerin expression 
to VSMCs is sufficient to accelerate atherosclerosis, trigger plaque vulnerability, 
and reduce lifespan. Our results identify progerin-induced VSMC death as a 
major factor triggering atherosclerosis and premature death in HGPS.
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Cardiovascular disease (CVD) is the leading cause of death worldwide, despite major recent prog-ress in its prevention, diagnosis, and treatment.1,2 
Atherosclerosis, defined as the narrowing of the arterial 
lumen because of atheroma plaque buildup, underlies 
most manifestations of CVD and can lead to myocardial 
infarction or stroke.
Accelerated atherosclerosis is a predominant fea-
ture of the rare genetic disorder Hutchinson-Gilford 
progeria syndrome (HGPS). Classical HGPS is caused by 
a point mutation (c.1824C>T; p.G608G) in the LMNA 
gene resulting in ubiquitous expression of progerin, a 
mutant form of the nuclear envelope protein lamin A.3,4 
Children with HGPS typically appear normal at birth, 
but within the first 2 years of life start to display the first 
signs of the disease, such as growth impairment and 
skin abnormalities. As childhood progresses, patients 
develop other symptoms, including alopecia, loss of 
body fat, joint stiffness, and osteoporosis, resembling 
many features of physiological aging.5,6 The most clini-
cally relevant feature of HGPS is generalized atheroscle-
rosis that leads to premature death from myocardial 
infarction or stroke at an average age of 14.6 years.5,7 
Atherosclerosis in HGPS is accompanied by pathologi-
cal changes in the aortic wall involving severe vascular 
smooth muscle cell (VSMC) depletion in the media, ex-
tracellular matrix deposition, calcification, and adventi-
tial thickening.8–10
Atherosclerotic disease in HGPS is particularly in-
triguing because patients lack the classical CVD risk 
factors, such as increased low-density lipoprotein (LDL) 
and C-reactive protein levels in serum.11 HGPS therefore 
offers a unique opportunity to study CVD in isolation 
from typical risk factors. Because progerin also accumu-
lates during normal aging,10,12,13 studies of HGPS may 
enhance our knowledge about physiological aging and 
CVD.14
As of October 1, 2017, there were 111 identified 
children living with HGPS worldwide, all of them carry-
ing a progerin-producing mutation in the LMNA gene.15 
This extremely low number presents major difficulties 
for research into disease mechanisms and for clinical 
trials testing new therapeutic strategies. Several mouse 
models of HGPS have been generated, including Lm-
naHG, BAC G608G, LmnaG609G, and Zmpste24–/–.16–22 
Although these mice recapitulate many aspects of the 
disease, none have been reported to develop athero-
sclerosis, the life-threatening symptom of HGPS. Thus, 
the aim of this study was to generate a mouse model 
exhibiting progerin-induced atherosclerosis accelera-
tion and to study the relative contribution to progerin-
driven atherosclerosis of macrophages and VSMCs, the 
key players in atherogenesis.
METHODS
The data, analytic methods, and study materials will be made 
available to other researchers for purposes of reproducing the 
results or replicating the procedure (available at the authors’ 
laboratories).
Study Approval
All experimental and other scientific procedures with animals 
conformed to EU Directive 2010/63EU and Recommendation 
2007/526/EC, enforced in Spanish law under Real Decreto 
53/2013. Animal protocols were approved by the local 
ethics committees and the Animal Protection Area of 
the Comunidad Autónoma de Madrid (PROEX76/14, 
PROEX78/14, PROEX167/16). Blood for LDL isolation was 
obtained from healthy volunteers after informed consent in 
accordance with local ethics committee guidelines (Comité de 
Ética de la Investigación del Instituto de Salud Carlos III: CEI 
PI 12_2016-v2).
Mice
All mice used in this study were males on the C57BL/6J 
genetic background carrying the following genetic manipu-
lations: Apoe–/– (The Jackson Laboratory, stock no: 002052), 
Clinical Perspective
What Is New?
• We have generated the first mouse model of 
progerin-induced acceleration of atherosclerosis, a 
major medical problem in patients with Hutchin-
son-Gilford progeria syndrome.
• We provide the first direct evidence that progerin 
expression restricted to vascular smooth muscle 
cells (VSMCs), but not to macrophages, is sufficient 
to induce premature atherosclerosis and death.
• We demonstrate that progerin-induced loss of 
VSMCs causes atherosclerotic plaque destabiliza-
tion that may lead to myocardial infarction.
• We show that ubiquitous and VSMC-specific 
progerin expression increases low-density lipopro-
tein retention in the aortic media, likely accelerat-
ing atherosclerosis.
What Are the Clinical Implications?
• Apoe–/–LmnaG609G/G609G mice ubiquitously express-
ing progerin constitute the first preclinical animal 
model for the study of accelerated atherosclerosis 
and premature aging.
• Apoe–/–LmnaLCS/LCSSM22αCre mice with VSMC-
specific progerin expression constitute the first 
preclinical animal model for the study of acceler-
ated atherosclerosis isolated from other disease 
symptoms.
• Because atherosclerosis is the main disease symp-
tom leading to death in patients with Hutchinson-
Gilford progeria syndrome, our studies point to 
VSMCs as a potential target for future therapies 
for this devastating disease.
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LmnaG609G/+,18 LmnaLCS/+,18 SM22αCre (TaglnCre, The Jackson 
Laboratory, stock no: 017491), and LysMCre.23 These lines 
were used to generate atherosclerosis-susceptible mouse 
models with ubiquitous progerin expression (Apoe–/–LmnaG609G/
G609G), VSMC-specific progerin expression (Apoe–/–LmnaLCS/
LCSSM22αCre), or macrophage (myeloid)-specific progerin 
expression (Apoe–/–LmnaLCS/LCSLysMCre), together with their 
corresponding controls expressing normal lamin A/C (Apoe–
/–Lmna+/+, used as control for Apoe–/–LmnaG609G/G609G) or lamin 
C only (Apoe–/–LmnaLCS/LCS used as control for cell type–specific 
models). Table I in the online-only Data Supplement  shows 
the expression pattern of lamin A, lamin C, and progerin in 
the above-mentioned models. To compare the atheroscle-
rosis-prone (Apoe–/–) and atherosclerosis-resistant (Apoe+/+) 
backgrounds, we bred LmnaLCS/LCSSM22αCre, LmnaLCS/LCS, 
LmnaG609G/G609G, and Lmna+/+ mice.
Longevity Studies
Starting at 4 weeks of age, animals were weighed and 
inspected for health and survival at least once a week (checks 
were more frequent for Apoe–/–LmnaG609G/G609G mice). Diseased 
animals were examined by a specialized veterinarian blinded 
to genotype. Animals that met humane end point criteria 
were euthanized and the deaths recorded. Animals eutha-
nized because of hydrocephalus, malocclusion, intermale 
aggression, or other reasons unconnected to phenotype were 
excluded from the analysis (normally at a very early stage of 
the study).
High-Fat Diet Experiments
For diet-induced atherosclerosis experiments, animals were 
maintained for 8 weeks on a high-fat diet (HFD) (10.7% 
total fat, 0.75% cholesterol, S9167-E010, Ssniff) starting at 8 
weeks of age. Mice were euthanized at 16 weeks of age after 
overnight fasting.
Hematology and Serum Biochemical 
Analysis
Animals were fasted overnight for all blood analyses, which 
were performed by specialized staff from the Centro Nacional 
de Investigaciones Cardiovasculares Carlos III (CNIC) Animal 
Facility. For hematology, blood samples were collected in 
Microvette 100 EDTA tubes (Sarstedt) and analyzed with a 
PENTRA 80 hematology analyzer (Horibo). For biochemical 
analysis, blood samples were collected in plastic tubes, incu-
bated at room temperature for 2 to 3 hours to allow clot-
ting, and centrifuged at 2000g for 5 minutes. Serum was 
stored at –80°C until samples from all experiments were col-
lected. Because of volume limitations, serum samples were 
pooled from 2 to 4 animals of the same experimental group. 
Specimens with overt hemolysis were excluded from testing. 
Biochemical variables were analyzed using a Dimension RxL 
Max Integrated Chemistry System (Siemens Healthineers).
Quantification of Atherosclerosis Burden
Mouse aortas were fixed in 4% formaldehyde/phosphate-
buffered saline (PBS), cleaned of fatty tissue, and stained with 
0.2% Oil Red O (ORO, O0625, Sigma). The thoracic aorta and 
aortic arch were then cut open longitudinally and pinned out 
flat, intimal side up, for computer-assisted planimetric analy-
sis. Images were taken with a digital camera (Olympus UC30) 
mounted on a stereo microscope (Olympus SZX3). The ORO-
stained lesion was quantified as a percentage of total area 
with SigmaScan Pro 5 (Systat Software Inc) by an observer 
blinded to genotype.
Histology and Immunofluorescence
For all mice with an Apoe–/– background, formaldehyde-fixed 
aortic arches were cleaned of fatty tissue, incubated in 30% 
sucrose in PBS overnight at 4°C, and included in Tissue-Tek 
OCT compound (Sakura) for cryostat sectioning. Serial 8-µm 
sections were stained with ORO, hematoxylin and eosin, and 
Masson trichrome. For immunofluorescence, sections were 
blocked and permeabilized for 1 hour at room temperature 
(RT) in PBS containing 0.3% Triton X-100 (9002-93-1, Sigma), 
5% bovine serum albumin (A7906, Sigma), and 5% nor-
mal goat serum (005-000-001, Jackson ImmunoResearch). 
Sections were then incubated for 2 hours at RT with anti–
smooth muscle α-actin-Cy3 (SMA-Cy3, C6198, Sigma, 1:200) 
antibody and overnight at 4°C with the following antibodies: 
anti-CD68 (MCA1957, Serotec, 1:200), and anti-progerin/
lamin A (sc-20680, Santa Cruz, 1:100). Next, samples were 
incubated with corresponding secondary antibodies (anti-
rat Alexa Fluor-568, A-11077 and anti-rabbit Alexa Fluor-
647, A-21245, Invitrogen) and Hoechst 33342 nucleic 
acid stain (B2261, Sigma) for 2 hours at RT and mounted 
in Fluoromount-G imaging medium (4958-02, Affymetrix 
eBioscience).
Aortic arches of LmnaLCS/LCSSM22αCre and LmnaLCS/LCS mice 
were fixed in 4% formaldehyde in PBS, cleaned of fatty tissue, 
dehydrated to xylene, and embedded in paraffin. Serial 4-µm 
sections were deparaffinized, rehydrated, and stained with 
hematoxylin and eosin and Masson trichrome.
Mouse hearts were fixed in 4% formaldehyde in PBS, 
divided into 2 parts (the upper portion containing the aortic 
root and aortic valve was separated for atheroma plaque anal-
ysis), dehydrated to xylene, and embedded in paraffin. Heart 
sections were prepared at least at 6 levels. The aortic root was 
sectioned throughout the aortic valve. Serial 4-µm sections 
were deparaffinized, rehydrated, and stained with hematoxy-
lin and eosin, Masson trichrome, von Kossa, and Perl Prussian 
blue. For immunofluorescence, antigen retrieval was per-
formed using 10 mmol/L sodium citrate buffer (pH 6). Then 
samples were blocked and permeabilized for 1 hour at RT in 
PBS containing 0.3% Triton X-100, 5% bovine serum albu-
min, and 5% normal goat serum, and incubated overnight 
at 4°C with anti-CD31 (ab28364, Abcam, 1:100) antibody, 
and for 2 hours at RT with anti-SMA-Cy3 antibody (C6198, 
Sigma, 1:200). Next, samples were incubated with anti-rabbit 
Alexa Fluor-647 secondary antibody (111-607-008, Jackson 
ImmunoResearch) and Hoechst 33342 for 2 hours at RT, and 
mounted in Fluoromount-G imaging medium.
ORO, hematoxylin and eosin, Masson trichrome, von 
Kossa, and Perls Prussian blue–stained sections were scanned 
with a NanoZoomer-RS scanner (Hamamatsu), and images 
were exported using NDP.view2. Immunofluorescence 
images were acquired with a Zeiss LSM700 confocal micro-
scope. Images were analyzed using ImageJ Fiji software by 
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an observer blinded to genotype. Aortic media and adventitia 
thickness and medial lipid and VSMC content were analyzed 
in ≈3 sections of aortic arch per animal, and mean values were 
used for statistical analysis. Atherosclerotic plaque area, aortic 
perimeter affected by atherosclerosis, necrotic core size, col-
lagen content, VSMC content, and plaque calcification were 
quantified in 3 different zones of the aortic root per animal 
(at the beginning, in the middle, and at the end of the aor-
tic valve), and mean values were used for statistical analysis. 
Cardiac alterations were assessed near the aortic valve and 
at least at 6 different levels of the ventricles by a specialized 
pathologist blinded to genotype.
mRNA Isolation and Reverse 
Transcription for PCR Detection of Lamin 
A and Progerin
Liver, kidney, spleen, and heart were homogenized using a 
TissueLyser (Qiagen), and total RNA was extracted with QIAzol 
reagent (Qiagen). The RNA pellet was dissolved in RNase-free 
water, and concentration was measured in a NanoDrop spec-
trophotometer (Wilmington). RNA (2 µg) was transcribed to 
cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems).
cDNA (200 ng) was amplified by PCR using DNA poly-
merase (Biotools). Lamin A and progerin mRNAs were 
detected according to a protocol adapted from Yang et al.24 
PCR products were separated on a 2% agarose gel contain-
ing ethidium bromide. Images were taken with a Molecular 
Imager Gel Doc XR+ System (BioRad) and analyzed with 
Image Laboratory (BioRad).
LDL Retention in Vivo
Fluorescently labeled human LDL was prepared as described.25 
In brief, human blood from healthy donors was collected in 
K3EDTA-containing tubes (455036, Vacuette). After centrifu-
gation, plasma was collected, mixed with KBr, and layered 
on a KBr density gradient column. The column was centri-
fuged at 256 000g for 18 hours in an Optima L-100 ultracen-
trifuge (Beckman). The 1.063 g/mL density layer containing 
LDL was collected, purified on a PD10 column (17085101, 
GE Healthcare), and conjugated to the fluorochrome Atto 
565 N-hydroxysuccinimide ester (72464, Sigma-Aldrich). 
Atto565-LDL was purified on a PD10 column, and purity was 
tested at the CNIC Proteomics Unit by liquid chromatography-
mass spectrometry (High Resolution Orbitrap-Fusion, Thermo 
Scientific) in an 8% to 27% acetonitrile gradient over 2 hours.
Mice received intravenous injections of Atto565-LDL (15 
µg/g body weight). Approximately 20 hours postinjection, 
animals were anesthetized with pentobarbital (Dolethal, 
Vetoquinol) and lidocaine (Lidocaine 20 mg/mL, B. Braun 
Medical S.A.) solution in saline (pentobarbital 1:5, lidocaine 
1:50) and perfused with 4% formaldehyde in PBS. Prefixed 
aortas were extracted, cleaned of fatty tissue, opened lon-
gitudinally, and pinned flat on a silicone-covered plate. After 
overnight fixing in 4% formaldehyde/PBS, aortas were cut 
into 3 pieces and mounted in glycerol on a microscope slide. 
Fluorescence images were acquired with a Zeiss LSM780 
confocal microscope. Autofluorescence (background) was 
determined in 2 mice (of each genotype) not injected with 
Atto565-LDL. ImageJ Fiji software was used to quantify the 
percentage of the aortic area positive for red fluorescence. 
Videos were prepared using Imaris software (Bitplane).
Electrocardiography 
Mice were anesthetized with 1.5% to 2% isoflurane, and 4 
electrocardiography (ECG) electrodes were inserted subcuta-
neously into the limbs. ECG was performed in the morning 
using the MP36R system (Biopac Systems). ECG data were 
analyzed with AcqKnowledge software (Biopac Systems) by 
specialized staff blinded to genotype.
Statistical Analysis
Experimental data are presented as the mean (error bars 
indicate SEM) for normally distributed data or median 
with interquartile range (error bars indicate minimum and 
maximum) for nonnormally distributed data. Based on all 
experiments, distribution of a variable (lesion size, nucleus 
count, etc) was assessed using the Kolmogorov-Smirnov 
and D’Agostino-Pearson normality tests. If the distribu-
tion was normal in most of the experiments, a 2-tailed t 
test was used. If the distribution of a variable was skewed, 
the 2-tailed Mann-Whitney test was used. To compare mul-
tiple groups, a 1-way ANOVA with the Tukey post hoc test 
was used for normally distributed data, and a Kruskal-Wallis 
test with the Dunn post hoc test was used for nonnormally 
distributed data. A log-rank (Mantel-Cox) test was used to 
compare Kaplan-Meier survival curves. Differences were 
considered significant at P<0.05. Statistical analysis was per-
formed with GraphPad Prism 5.
RESULTS
Ubiquitous Progerin Expression in Apoe–/– 
Mice Accelerates Atherosclerosis
LmnaG609G/G609G knock-in mice ubiquitously expressing 
progerin recapitulate most clinical manifestations of 
HGPS, including postnatal growth impairment, lipodys-
trophy, vascular calcification, and reduced survival (av-
erage lifespan: ≈15 weeks).18,26 However, we observed 
no atherosclerosis in aortas of LmnaG609G/G609G mice even 
when animals were challenged with a HFD for 8 weeks 
starting at 8 weeks of age (Figure I in the online-only 
Data Supplement). This finding is consistent with the 
observation that mice, unlike humans, are extremely re-
sistant to atherosclerosis development, in part, because 
of differences in cholesterol and lipoprotein metabo-
lism.27 To circumvent this limitation, we generated an 
atherosclerosis-prone mouse model of HGPS by cross-
ing LmnaG609G/+ mice with apolipoprotein E–deficient 
(Apoe–/–) mice, a widely used atherosclerosis model.27 
As expected, Apoe–/–LmnaG609G/G609G mice showed re-
duced body weight and a shortened lifespan (median 
survival, 18.15 weeks) in comparison with Apoe–/–Lm-
na+/+ littermates with an intact Lmna gene (Figure 1A 
through 1C).
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To study the influence of progerin on atherosclerosis, 
8-week-old mice were challenged for 8 weeks with a 
HFD and euthanized at 16 weeks of age. Pre-HFD serum 
lipid levels, including total cholesterol, free cholesterol, 
LDL, and high-density lipoprotein were indistinguishable 
between experimental groups (Figure  1D). However, 
post-HFD levels were significantly lower in 16-week-
old Apoe–/–LmnaG609G/G609G mice than in age-matched 
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Figure 1. Ubiquitous progerin expression in Apoe–/–LmnaG609G/G609G mice impairs postnatal growth, reduces lifespan, and accelerates atherosclerosis.  
A, Postnatal body weight curves for Apoe–/–Lmna+/+ mice (n=7) and Apoe–/–LmnaG609G/G609G mice (n=14). B, Kaplan-Meier survival curves. Median survival: 18.15 
weeks for Apoe–/–LmnaG609G/G609G mice (n=14) and 117.6 weeks for Apoe–/–Lmna+/+ mice (n=7). C, Representative photograph of 16-week-old males. Scale bar: 1 
cm. D, Pre–high-fat diet (HFD) serum levels of total cholesterol, free cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in 8-week-old 
Apoe–/–LmnaG609G/G609G mice (n=5) and Apoe–/–Lmna+/+ mice (n=7). E, Post-HFD serum levels of total cholesterol, free cholesterol, LDL, and HDL in 16-week-old 
Apoe–/–LmnaG609G/G609G mice (n=6) and Apoe–/–Lmna+/+ mice (n=8). F, Representative aortic arches (Top) and thoracic aortas (Middle and Bottom) stained with 
Oil Red O; graphs show quantification of atherosclerosis burden in Apoe–/–LmnaG609G/G609G mice (n=9 aortic arches; n=12 thoracic aortas) and Apoe–/–Lmna+/+ mice 
(n=6 aortic arches; n=13 thoracic aortas). Scale bar: 2 mm. Studies in A, B, and C were performed with mice fed normal chow, and those in D, E, and F were 
conducted with mice fed the HFD for 2 months starting at 8 weeks of age. Data are shown as mean±SEM in A, D, and E, and as median with interquartile range 
and minima and maxima in F. Statistical differences were analyzed by log-rank test in B, by 2-tailed t test in A, D, and E, and by 2-tailed Mann-Whitney test in F. 
*P<0.05. **P<0.01. ***P<0.001.
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Apoe–/–Lmna+/+ controls (Figure  1E), probably because 
of reduced food intake associated with the advanced 
disease progression in progeroid mice. HFD-fed Apoe–/–
LmnaG609G/G609G mice nonetheless had a 1.9-fold higher 
atherosclerosis burden in the aortic arch and a 2.8-fold 
higher burden in the thoracic aorta (Figure  1F) as as-
sessed by ORO staining. Although both groups had fo-
cal aortic lesions, the aortic surface of progeroid Apoe–/–
LmnaG609G/G609G mice was largely covered with lipid 
deposits that were not seen in control Apoe–/–Lmna+/+ 
mice (Figure 1F, high magnification in bottom images). 
Histological examination revealed that this abnormality 
was attributable to excessive lipid accumulation in the 
aortic tunica media in atheroma-free zones of Apoe–/–
LmnaG609G/G609G aorta (Figure  2A). It is remarkable that 
Apoe–/–LmnaG609G/G609G mice developed other patholo-
gies present in patients with HGPS, including adventitial 
thickening (Figure 2A) and massive loss of VSMCs within 
the media (Figure 2B). Apoe–/–LmnaG609G/G609G mice also 
showed significant hematologic alterations, including 
lower pre- and post-HFD lymphocyte and monocyte 
counts (Figure II in the online-only Data Supplement).
VSMC-Specific, But Not Macrophage-
Specific, Progerin Expression in Apoe–/– 
Mice Aggravates Atherosclerosis and 
Shortens Lifespan
Atherosclerosis is a multifactorial process involving 
many cell types, including VSMCs and macrophages.28,29 
Immunohistopathological characterization of athero-
sclerotic plaques in patients with HGPS suggests that 
both cell types contribute to progerin-driven athero-
genesis.10 Because Apoe–/–LmnaG609G/G609G mice showed 
medial VSMC loss and reduced numbers of circulating 
monocytes (which differentiate to macrophages in ath-
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Figure 2. Apoe–/–LmnaG609G/G609G mice with ubiquitous progerin expression exhibit severe vascular pathology, including lipid retention and vascular 
smooth muscle cell (VSMC) loss in the media, and adventitial thickening.  
Mice were fed a high-fat diet for 8 weeks starting at 8 weeks of age. A, Representative staining of aorta sections with Oil Red O (ORO) and hematoxylin and eosin 
(H&E). Graphs show quantification of lipid content in atheroma-free zones of the media (as % of the ORO-positive area) and adventitia-to-media thickness ratio; 
n=6 to 8. Scale bar: 50 µm. B, Representative immunofluorescence images of aortas stained with anti–smooth muscle actin (SMA) antibody (red) and Hoechst 
33342 (blue). Graphs show quantification of VSMC content in the media as either nucleus count or % of SMA-positive area; n=5 to 8. Scale bar: 50 µm. Box and 
whisker plots in A show medians, interquartile range, and minima and maxima; data in B are mean±SEM. Statistical analysis was performed by 2-tailed Mann-
Whitney test in A, and 2-tailed t test in B. ***P<0.001. a indicates adventitia; and m, media.
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eromata), we generated mice with specific progerin 
expression in VSMCs or macrophages to study the 
relative contribution of these cell types to the vascular 
pathology induced by progerin. We used knock-in Lm-
naLCS/LCS mice expressing only lamin C, which produce 
progerin on crossing with transgenic mice expressing 
Cre recombinase.18 LmnaLCS/LCS mice are apparently nor-
mal, but are slightly heavier and longer-lived than wild-
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Figure 3. Vascular smooth muscle cell (VSMC)–specific progerin expression in Apoe–/–LmnaLCS/LCSSM22αCre mice reduces lifespan and accelerates athero-
sclerosis.  
A, Postnatal body weight curves for Apoe–/–LmnaLCS/LCS mice (n=9), Apoe–/–LmnaLCS/LCSSM22αCre mice (n=12), and Apoe–/–LmnaLCS/LCSLysMCre mice (n=6). The weight curve 
for Apoe–/–LmnaLCS/LCSSM22αCre mice is shown up to the time when ≈90% of the animals were dead. B, Kaplan-Meier survival curves. Median survival: 34.3 weeks for 
Apoe–/–LmnaLCS/LCSSM22αCre mice (n=17), 106.3 weeks for Apoe–/–LmnaLCS/LCS mice (n=9), and 116.3 weeks for Apoe–/–LmnaLCS/LCSLysMCre mice (n=6). C, Representative 
photograph of 16-week-old males. Scale bar: 1 cm. D, Pre–high-fat diet (HFD) serum levels of total cholesterol, free cholesterol, low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) in 8-week-old Apoe–/–LmnaLCS/LCS mice (n=5), Apoe–/–LmnaLCS/LCSSM22αCre mice (n=4), and Apoe–/–LmnaLCS/LCSLysMCre mice (n=6). E, Post-HFD 
serum levels of total cholesterol, free cholesterol, LDL, and HDL in 16-week-old Apoe–/–LmnaLCS/LCS mice (n=10), Apoe–/–LmnaLCS/LCSSM22αCre mice (n=7), and Apoe–/–
LmnaLCS/LCSLysMCre mice (n=7). F, Representative examples of thoracic aortas stained with Oil Red O (ORO). The graph shows quantification of atherosclerosis burden 
in Apoe–/–LmnaLCS/LCS mice (n=24), Apoe–/–LmnaLCS/LCSSM22αCre mice (n=17), and Apoe–/–LmnaLCS/LCSLysMCre mice (n=19). Scale bar: 2 mm. Studies in A, B, and C were 
performed with mice fed normal chow, and those in D, E, and F were conducted with mice fed the HFD for 2 months starting at 8 weeks of age. Data in A, D, and 
E are mean±SEM. Box and whisker plots in F show medians, interquartile range, and minima and maxima. Statistical analysis was performed by log-rank test in B, by 
1-way ANOVA with the Tukey post hoc test in A, D and E, and by the Kruskal-Wallis test with the Dunn post hoc test in F. ***P<0.001.
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type controls.30 We generated Apoe–/–LmnaLCS/LCS mice 
and analyzed atherosclerosis in 16-week-old mice that 
received a HFD during the last 8 weeks. In comparison 
with control Apoe–/–Lmna+/+ littermates, Apoe–/–LmnaLCS/
LCS mice showed no significant differences in atheroscle-
rosis burden, serum lipid levels, or hematologic param-
eters (Figure III in the online-only Data Supplement).
These results demonstrated that Apoe–/–LmnaLCS/LCS 
mice could serve as controls for the macrophage-specif-
ic Apoe–/–LmnaLCS/LCSLysMCre and VSMC-specific Apoe–/–
LmnaLCS/LCSSM22αCre models. Progerin expression was 
examined by immunofluorescence in atheroma-contain-
ing aorta and by PCR in other organs. Apoe–/–LmnaLCS/
LCS mice did not express progerin in any organ tested 
(Figures IV and V in the online-only Data Supplement). 
Apoe–/–LmnaLCS/LCSSM22αCre mice abundantly expressed 
progerin in VSMCs of the media, to a lesser extent in 
the adventitia (Figure IV in the online-only Data Supple-
ment), and also in heart (Figure V in the online-only Data 
Supplement). Progerin expression in Apoe–/–LmnaLCS/
LCSLysMCre mice was detected in intimal macrophages 
(Figure IV in the online-only Data Supplement), but was 
either absent or negligible in other organs (Figure V in 
the online-only Data Supplement).
Apoe–/–LmnaLCS/LCSLysMCre mice with macrophage-
specific progerin expression showed no significant dif-
ferences in organ size (Figure VI in the online-only Data 
Supplement), body weight, or longevity compared with 
controls (Figure 3A through 3C). Although Apoe–/–Lm-
naLCS/LCSSM22αCre mice with VSMC-specific progerin 
expression appeared normal early in life (Figure 3C and 
Figure VI in the online-only Data Supplement), they 
stopped gaining weight from ≈20 weeks of age (Fig-
ure 3A), and died prematurely at a median age of 34.3 
weeks (Figure 3B). Atherosclerosis was studied with the 
same protocol used for the ubiquitously progerin-ex-
pressing Apoe–/–LmnaG609G/G609G mice. The 3 experimental 
groups showed no intergroup differences in serum lipid 
levels (Figure  3D and 3E) or hematologic parameters 
(Figure VII in the online-only Data Supplement), either 
pre- or post-HFD. Atherosclerosis burden in the tho-
racic aorta was similar in Apoe–/–LmnaLCS/LCSLysMCre and 
Apoe–/–LmnaLCS/LCS mice; in contrast, the lesion burden in 
Apoe–/–LmnaLCS/LCSSM22αCre mice was 4.4-fold higher 
(Figure  3F). Moreover, histological analysis in Apoe–/–
LmnaLCS/LCSSM22αCre mice revealed the same marked 
aortic phenotype observed in the ubiquitous progeroid 
model, including massive VSMC loss, lipid accumulation 
in the media, and adventitial thickening (Figure 4).
Progerin Expression Accelerates 
Atherosclerosis in Apoe–/– Mice Fed 
Normal Chow
To gain insight into the progress of progerin-in-
duced atherogenesis and to assess the role of cho-
lesterol in this process, we performed experiments 
in 8- and 16-week-old mice fed normal chow. His-
tological examination of aortas from 8-week-old 
mice revealed no differences between the progeroid 
models and their controls, with tissue almost free 
of atherosclerosis and no obvious structural altera-
tions (Figure VIIIA, VIIIC, and VIIIE in the online-only 
data supplement). In contrast, the thoracic aortas of 
16-week-old Apoe–/–LmnaG609G/G609G and Apoe–/–Lm-
naLCS/LCSSM22αCre mice presented increased lesion 
formation than their controls (Figure VIIIB and VIIID 
in the online-only Data Supplement). Furthermore, 
aortas of both mutant models contained regions 
with VSMC loss (Figure VIIIE in the online-only Data 
Supplement). This vascular phenotype was slightly 
more pronounced in Apoe–/–LmnaLCS/LCSSM22αCre 
mice than in Apoe–/–LmnaG609G/G609G mice, with lipid 
retention in the media and adventitial thickening 
(data not shown), probably because of normal food 
intake and a consequent cholesterol level similar to 
that of control mice.
Aortas of Apoe–/–LmnaG609G/G609G and 
Apoe–/–LmnaLCS/LCSSM22αCre Mice Show 
Increased LDL Retention
Lipid accumulation in the aortic medial layer is a 
prominent characteristic of the vascular pathology in 
both the ubiquitous and the VSMC-specific progeroid 
mouse models. Because LDL retention in the aortic 
wall is one of the key processes triggering athero-
sclerosis initiation and progression, we performed 
in vivo LDL retention experiments by injecting nor-
mal chow–fed 16-week-old mice with human LDL 
labeled with the fluorochrome Atto565 (Figure 5A). 
Aortic Atto565-LDL content was quantified 20 hours 
postinjection, at which time exogenous human LDL 
is cleared from the circulation.25 In comparison with 
their respective control littermates, both Apoe–/–Lm-
naG609G/G609G and Apoe–/–LmnaLCS/LCSSM22αCre mice 
showed increased aortic LDL retention (Figure 5B and 
5C and Figure IXA and IXB in the online-only Data 
Supplement). Although Atto565-LDL was localized in 
the intimal lesions in mice of all genotypes, its ex-
cessive retention in the medial layer was exclusive to 
the ubiquitous and VSMC-specific progeria mouse 
models (Figure 5D and 5E, Figure IXC and IXD in the 
online-only Data Supplement and Movies I through 
XVI in the online-only Data Supplement).
Progerin Triggers Plaque Vulnerability
Previous studies have shown that VSMC loss in the 
tunica media can promote atherosclerotic plaque in-
stability31; we therefore characterized atherosclerotic 
lesions in the aortic root. Consistent with our results 
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in the aorta (Figures  1F and 3F), analysis of athero-
mata in the aortic root revealed a larger lesion area 
in HFD-fed Apoe–/–LmnaG609G/G609G and Apoe–/–LmnaLCS/
LCSSM22αCre mice than in their respective controls, 
and this was accompanied by fibrosis and inflamma-
tion in the adjacent cardiac tissue (Figure 6A and 6B). 
Moreover, atherosclerosis affected a higher percent-
age of the aortic surface in both models (Figure 6A 
and 6B). Analysis of Apoe–/–LmnaG609G/G609G and Apoe–/–
LmnaLCS/LCSSM22αCre mice revealed the presence in 
atheromata of erythrocytes, indicating healed plaque 
fissures (Figure 6C and 6D, top). We also found hem-
orrhage in the aortic valve itself (Figure 6C, bottom), 
and evidence of thrombus formation (Figure  6D, 
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Figure 4. Apoe–/–LmnaLCS/LCSSM22αCre mice with vascular smooth muscle cell (VSMC)–specific progerin expression show severe vascular pathology, 
including VSMC loss and lipid retention in the media and adventitial thickening.  
Mice were fed a high-fat diet for 8 weeks starting at 8 weeks of age. A, Representative staining of aorta sections with Oil Red O (ORO) and hematoxylin and eosin 
(H&E). Graphs show quantification of lipid content in atheroma-free zones of the media (% of ORO-positive area) and adventitia-to-media thickness ratio; n=6 
to 8. Scale bar: 50 µm. B, Representative immunofluorescence images of aortas stained with anti–smooth muscle actin (SMA) antibody (red) and Hoechst 33342 
(blue). Graphs show quantification of VSMC content in the media as either nucleus count or % of SMA-positive area; n=6 to 8. Scale bar: 50 µm. Box and whisker 
plots in A show medians, interquartile range, and minima and maxima; data in B are mean±SEM. Statistical analysis was performed by the Kruskal-Wallis test with 
the Dunn post hoc test in A and by 1-way ANOVA with the Tukey post hoc test in B. *P<0.05. **P<0.01. ***P<0.001. a indicates adventitia; and m, media.
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bottom), which might be related to plaque erosion. 
Accordingly, atheromata in both models showed fea-
tures of vulnerable plaques (Table II in the online-only 
Data Supplement), including larger necrotic cores 
(Figure 7A and 7B), iron deposits (Figure 7C and 7D), 
and VSMC loss and disorganization in the fibrous cap 
(Figure 7E and 7F).
Apoe–/–LmnaG609G/G609G Mice Develop 
Cardiac Electric Defects
Previous studies reported cardiac electric defects in 
progeroid LmnaG609G/G609G and Zmpste24-deficient (Zmp-
ste24–/–) mice similar to those found in patients with 
HGPS.6,18,32 We therefore performed ECG in the ubiqui-
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mount tissue. B and C, Representative tile scan images of aortas from mice of the indicated genotypes; graphs show quantification of Atto565-LDL retention 
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mean±SEM. Statistical analysis was performed by 2-tailed t test. *P<0.05. **P<0.01. ***P<0.001.
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Figure 6. Enhanced aortic root atherosclerosis in Apoe–/–LmnaG609G/G609G and Apoe–/–LmnaLCS/LCSSM22αCre mice is accompanied by inflammation of adja-
cent cardiac tissue and plaque destabilization.  
Mice were fed a high-fat diet for 8 weeks starting at 8 weeks of age. Serial sections of the aortic root were made and 3 different regions were stained with Masson 
trichrome. A and B, Representative photographs of atheromata in the aortic root of Apoe–/–LmnaG609G/G609G mice (A) and Apoe–/–LmnaLCS/LCSSM22αCre mice (B), and 
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D
ow
nloaded from
 http://ahajournals.org by on November 21, 2019
Hamczyk et al Atherosclerosis in Progeria
Circulation. 2018;138:266–282. DOI: 10.1161/CIRCULATIONAHA.117.030856 July 17, 2018 277
ORIGINAL RESEARCH 
ARTICLE
tous and VSMC-specific progeria models. As expected, 
16-week-old Apoe–/–LmnaG609G/G609G mice exhibited se-
vere bradycardia and prolonged QRS, QT, and QTc in-
tervals (Figure XA in the online-only Data Supplement). 
Moreover, 2 of 5 mice had arrhythmias (Figure XB in the 
online-only Data Supplement). In contrast, 16-week-
old Apoe–/–LmnaLCS/LCSSM22αCre mice presented no evi-
dent ECG alterations (Figure XIA in the online-only Data 
Supplement). Nevertheless, follow-up revealed a low-
voltage QRS complex at 26 weeks of age (Figure IXB in 
the online-only Data Supplement), consistent with loss 
of viable myocardial tissue attributable to myocardial 
infarction. Likewise, many of the 26-week-old Apoe–/–
LmnaLCS/LCSSM22αCre mice exhibited T-wave fattening or 
inversion (Figure IXB in the online-only Data Supplement 
and data not shown), further supporting the notion that 
these animals develop age-associated cardiac alterations 
probably caused by progressive atherosclerosis.
Apoe–/–LmnaLCS/LCSSM22αCre Mice Die of 
Atherosclerosis-Related Causes
Despite an almost identical vascular phenotype, ubiq-
uitous and VSMC-specific atherosclerosis-prone pro-
geria models differed in their cardiac phenotype and 
median survival (18.15 weeks versus 34.3 weeks, re-
spectively). Apoe–/–LmnaLCS/LCSSM22αCre mice, which 
showed no overt aging phenotype, died suddenly 
between 26 and 66 weeks of age. It is interesting 
to note that LmnaLCS/LCSSM22αCre mice with an in-
tact Apoe gene also presented VSMC loss and aortic 
adventitial thickening, but did not develop athero-
sclerosis and had a normal lifespan (Figure XII in the 
online-only Data Supplement). These findings point 
to progerin-driven atherosclerosis as the main cause 
of death in Apoe–/–LmnaLCS/LCSSM22αCre mice. In con-
trast, Apoe–/–LmnaG609G/G609G mice progressively lost fat 
tissue, developed bone problems and muscle weak-
ness, and died between 15 and 24 weeks of age, a 
median survival very similar to that of atherosclerosis-
free LmnaG609G/G609G mice.18 We therefore conclude 
that the cause of death is likely different in the ubiq-
uitous and VSMC-specific progeria models, at least in 
the majority of the cases.
To analyze cardiovascular alterations, which could 
reveal the cause of death, we collected aortas and 
hearts from chow-fed Apoe–/–LmnaG609G/G609G and 
Apoe–/–LmnaLCS/LCSSM22αCre mice at an age close to 
their maximum survival (21–23 weeks and 51 weeks, 
respectively). Atherosclerosis burden in the aortic arch 
and thoracic aorta was significantly higher in Apoe–/–
LmnaG609G/G609G mice than in Apoe–/–Lmna+/+ controls 
(Figure 8A). In comparison with Apoe–/–LmnaLCS/LCS con-
trols, Apoe–/–LmnaLCS/LCSSM22αCre mice showed a high-
er lesion burden in the thoracic aorta but not in the 
aortic arch (Figure 8B), likely because this athero-prone 
aortic region is saturated with plaques in 51-week-old 
(≈1 year) Apoe–/– mice. It is important to note that vas-
cular pathology was much more severe in the aorta of 
51-week-old Apoe–/–LmnaLCS/LCSSM22αCre mice than in 
21- to 23-week-old Apoe–/–LmnaG609G/G609G mice (Fig-
ure 8A through 8C).
Consistent with the findings in the aorta, patho-
logical findings in the aortic root were more severe 
in Apoe–/–LmnaLCS/LCSSM22αCre mice than in Apoe–/–
LmnaG609G/G609G mice (Figures XIII through XVI in the 
online-only Data Supplement). Plaques in Apoe–/–Lm-
naG609G/G609G mice were generally immature, frequently 
exhibiting intraplaque hemorrhages that were absent 
in age-matched controls (Figure XIIIA in the online-
only Data Supplement). Of the Apoe–/–LmnaG609G/G609G 
animals, 3 of 9 showed signs of coronary athero-
sclerosis (Figure XVI, zone 1, in the online-only Data 
Supplement). In Apoe–/–LmnaLCS/LCSSM22αCre mice, 
atheromas were mature and severely calcified, and 
many of them had chondroid metaplasia (Figures XIII 
and XIV in the online-only Data Supplement). The 
noncalcified atheromas had thin fibrous caps and 
large necrotic cores (Figure XIIIA in the online-only 
Data Supplement). Moreover, 4 of 9 of the analyzed 
Apoe–/–LmnaLCS/LCSSM22αCre mice developed coronary 
atherosclerosis (Figure XVI, zone 1, in the online-only 
Data Supplement). Even though plaques of both mu-
tant models showed features of vulnerable plaques, 
such as lower collagen and VSMC content (Figure XIIIB 
in the online-only Data Supplement), Apoe–/–LmnaLCS/
LCSSM22αCre mice had more atherosclerosis, fibrosis, 
and inflammation in the aortic root (Figure XV in the 
online-only Data Supplement).
We also performed a histopathologic evaluation 
of the heart ventricles. Apoe–/–LmnaG609G/G609G hearts 
were characterized by cardiomyocyte vacuolization, 
which was absent in Apoe–/–Lmna+/+, Apoe–/–LmnaLCS/
LCSSM22αCre, and Apoe–/–LmnaLCS/LCS mice (Figure XVII in 
the online-only Data Supplement and data not shown). 
Furthermore, 3 of 9 Apoe–/–LmnaG609G/G609G hearts had 
coronary atherosclerosis (Figure  8D and Figure XVI in 
the online-only Data Supplement) and 2 had a colla-
gen scar in the septum, indicative of a nonfatal infarct 
(Figure XVIII in the online-only Data Supplement). Nev-
ertheless, many of the animals analyzed showed no 
detectable alterations apart from the cardiomyocyte 
vacuolization (Figure 8D and 8E).
Most Apoe–/–LmnaLCS/LCSSM22αCre hearts presented 
perivascular and interstitial fibrosis, intimal hyperplasia 
(without cellular infiltrates) and coronary atherosclerosis 
(Figure  8D and 8E, Figures XV and XVI in the online-
only Data Supplement). Some of the animals analyzed 
also showed evidence of coronary plaque calcification 
(Figure 8D). These pathological alterations in the heart 
suggest that Apoe–/–LmnaLCS/LCSSM22αCre animals are, 
like patients with HGPS, susceptible to microinfarcts 
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during their lifetime (Figure 8E). Collectively, these histo-
pathologic findings in the aorta and heart indicate that 
Apoe–/–LmnaLCS/LCSSM22αCre animals die of atheroscle-
rosis complications, whereas Apoe–/–LmnaG609G/G609G mice 
mostly die of atherosclerosis-independent processes.
DISCUSSION
Several mouse models of HGPS have been generat-
ed16–22; however, only a few of these models presented 
cardiovascular alterations and none showed evidence 
of atherosclerosis, the pathological process that leads 
to myocardial infarction– or stroke-related death in 
most children with HGPS. Based on these models, vari-
ous molecular mechanisms have been proposed to ex-
plain how progerin drives HGPS. Treatments targeting 
candidate pathways have significantly ameliorated dis-
ease progression and extended lifespan in mice; how-
ever, these treatments have only had modest thera-
peutic effects in patients with HGPS.33–35 One possible 
explanation is that progeric mice, unlike humans, die of 
atherosclerosis-independent causes. It is important to 
note that mice are particularly resistant to atheroscle-
rotic plaque formation, in part, because of the murine 
blood lipid profile, with high atheroprotective high-
density lipoprotein and low atherogenic LDL.36 Thus, 
to study atherosclerosis in mouse models, it is usually 
necessary to introduce a genetic mutation (such as in-
A B
C D
E F
Figure 7. Vulnerable plaque features in Apoe–/–LmnaG609G/G609G and Apoe–/–LmnaLCS/LCSSM22αCre mice.  
Mice were fed a high-fat diet for 8 weeks starting at 8 weeks of age, and aortas were extracted for histology and immunofluorescence. Representative images are 
shown. A and B, Hoechst 33342 staining to visualize nuclei (blue). Scale bar: 50 µm. C and D, Perls Prussian blue staining in atherosclerotic plaques to visualize cells 
with iron deposits (blue; arrows). Scale bar: 50 µm. E and F, Smooth muscle actin (SMA, visualized in red), endothelium (CD31, visualized in white), and nuclei (Hoechst 
33342, visualized in blue). Arrows mark the luminal part of the plaque (fibrous cap). Scale bar: 50 µm. A indicates adventitia; M, media; NC, necrotic core; and P, plaque.
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activation of the Apoe or Ldlr genes), to alter their lipid 
metabolism and make them more prone to developing 
atherosclerosis.37,38
In this study, we generated Apoe–/–LmnaG609G/G609G 
mice, the first mouse model of progerin-induced ath-
erosclerosis acceleration. In addition to enhanced ath-
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Apoe-/-LmnaG609G/G609G 4/9 3/9 3/9 2/9 0/9
Apoe-/-LmnaLCS/LCS 2/11 3/11 1/11 1/11 0/11
Apoe-/-LmnaLCS/LCSSM22αCre 8/9 8/9 9/9 8/9 2/9
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LV
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D
Figure 8. More severe cardiovascular phenotype in Apoe–/–LmnaLCS/LCSSM22αCre mice than in Apoe–/–LmnaG609G/G609G at ages close to their maximum 
survival.  
Mice were fed normal chow and euthanized at either 21 to 23 weeks of age (Apoe–/–LmnaG609G/G609G and control Apoe–/–Lmna+/+ mice) or 51 weeks of age (Apoe–/–
LmnaLCS/LCSSM22αCre and control Apoe–/–LmnaLCS/LCS mice). A, Representative Oil Red O (ORO) staining in aortas from Apoe–/–LmnaG609G/G609G and Apoe–/–Lmna+/+ 
mice. Graphs show quantification of atherosclerosis burden in the aortic arch and thoracic aorta; n=6. Scale bar: 2 mm. B, Representative ORO staining in aortas 
from Apoe–/–LmnaLCS/LCSSM22αCre and Apoe–/–LmnaLCS/LCS mice. Graphs show quantification of atherosclerosis burden in the aortic arch and thoracic aorta; n=5 to 6. 
Scale bar: 2 mm. C, Higher magnification of ORO-stained thoracic aortas of the indicated genotypes. Scale bar: 1 mm. D, Table summarizing cardiac pathologies 
assessed in 9 to 11 mice per genotype. Serial heart sections (at least at 6 different levels of the ventricles) were stained with Masson trichrome and analyzed. E, 
Representative heart sections from Apoe–/–LmnaG609G/G609G and Apoe–/–LmnaLCS/LCSSM22αCre mice. Blue staining indicates fibrosis. Scale bar: 1 mm (whole cross sec-
tion) and 200 µm (magnified view in insert). Data in A and B are shown as median with interquartile range and minima and maxima. Statistical differences were 
analyzed by 2-tailed Mann-Whitney test. *P<0.05. **P<0.01. LV indicates left ventricle; RV, right ventricle; and S, septum. 
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eroma plaque formation, these animals exhibit mas-
sive loss of medial VSMCs and prominent adventitial 
thickening and fibrosis, important hallmarks of vascu-
lar disease in HGPS.8–10 These features were previously 
observed in knock-in LmnaG609G/G609G and transgenic 
G608G BAC mouse models17–19; however, in earlier 
models, these features did not manifest as early or as 
severely as described here and were not accompanied 
by atherosclerosis development. The Apoe–/–LmnaG609G/
G609G model is also the first to show lipid accumulation 
in atheroma-free zones of the aortic media, which may 
contribute to enhanced plaque formation. Further-
more, our studies with Apoe–/–LmnaLCS/LCSSM22αCre 
mice (VSMC-specific progerin expression) and Apoe–/–
LmnaLCS/LCSLysMCre mice (macrophage-specific progerin 
expression) provide the first direct evidence that re-
stricting progerin expression to VSMCs, but not mac-
rophages, is sufficient to accelerate atherosclerosis and 
reduce lifespan. Although limiting progerin expression 
to macrophages does not increase atherosclerosis bur-
den or reduce survival, it remains to be determined 
whether it affects plaque composition. Further studies 
are also required to ascertain why progerin-expressing 
Apoe–/– mice have increased lipid retention in the media 
(eg, increased vascular permeability, changes in the ex-
tracellular matrix amount and composition).
Our findings in both the ubiquitous and the VSMC-
specific progerin mouse models indicate that VSMCs are 
particularly sensitive to progerin accumulation. Proger-
in-induced VSMC death results in increased LDL reten-
tion in the media, adventitial thickening, and acceler-
ated atherosclerosis. Similarly to Clarke et al,31 we found 
that VSMC death triggers features of plaque vulnerabil-
ity, which may lead to myocardial infarction and pre-
mature death. Our results demonstrate the importance 
of VSMCs in progerin-driven atherosclerosis and identify 
this cell type as a key target for future treatments.
It is remarkable that we observed that Apoe–/–Lm-
naG609G/G609G mice have a similar average lifespan to non-
atherosclerotic LmnaG609G/G609G mice, suggesting that 
mice with ubiquitous progerin expression die of ath-
erosclerosis-independent causes, unlike human patients 
with HGPS. In contrast, Apoe–/–LmnaLCS/LCSSM22αCre 
mice appear to die of atherosclerosis-related problems, 
because LmnaLCS/LCSSM22αCre mice, with VSMC-specific 
progerin expression but an intact Apoe gene, did not de-
velop atherosclerosis and had a normal lifespan. This hy-
pothesis is supported by histopathologic findings in mice 
at ages close to their maximum survival, which reveal 
much more severe aortic and coronary atherosclerosis 
in Apoe–/–LmnaLCS/LCSSM22αCre mice than in Apoe–/–Lm-
naG609G/G609G mice. It may be that plaque disruption lead-
ing to infarction and death occurs in Apoe–/–LmnaG609G/
G609G mice, but only in animals surviving to near 26 weeks 
of age. This is well beyond the median survival in this 
model (18.15 weeks), but is the age at which Apoe–/–Lm-
naLCS/LCSSM22αCre mice begin to die. Although Apoe–/–
LmnaG609G/G609G mice may die of heart failure, the cause 
would likely be related to complications such as arrhyth-
mia, rather than atherosclerosis, as supported by ECG 
studies in this model. Similarly, we previously reported 
that LmnaG609G/G609G mice have a prolonged QRS-complex 
duration, indicating defective cardiac conduction.18 Like-
wise, our studies in Zmpste24-null mice, another model 
of premature aging caused by defective prelamin A pro-
cessing, revealed PQ and QRS prolongation and T-wave 
flattening, which may increase the risk of lethal arrhyth-
mias in the setting of progeria.32 This result is also consis-
tent with the observation that patients with HGPS show 
repolarization abnormalities resulting in an increased risk 
of arrhythmias and premature death.32
In summary, atherosclerosis-prone Apoe–/–LmnaG609G/
G609G mice faithfully recapitulate most aspects of human 
HGPS, including growth retardation, shortened lifespan, 
and early CVD onset, and is therefore a valuable tool 
for investigation of the general mechanisms underlying 
HGPS. We have also demonstrated that VSMC-restrict-
ed progerin expression in Apoe–/–LmnaLCS/LCSSM22αCre 
mice is sufficient to induce the vascular features of pro-
geria independently of growth retardation and other 
disease symptoms, thus providing a unique preclini-
cal model for the study of atherosclerosis and athero-
sclerosis-associated premature death in isolation from 
other signs of premature aging. Another advantage of 
these animals is the lack of overt growth defects, which 
might permit the testing of diagnostic techniques and 
interventional strategies that are unavailable in the un-
dersized Apoe–/–LmnaG609G/G609G model.
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